Upgrade to Pro — share decks privately, control downloads, hide ads and more …

12-2-20 - Heart Failure and Mechanical Support ...

us414
December 02, 2020

12-2-20 - Heart Failure and Mechanical Support - Dr. Raffel

12-2-20 - Heart Failure and Mechanical Support - Dr. Raffel

us414

December 02, 2020
Tweet

More Decks by us414

Other Decks in Education

Transcript

  1. Heart Failure Heart Faulure • Approximate 6 million people have

    congestive HF – Incidence • 15.2 per 1000 after age 65 • 31.7 per 1000 after age 75 • 65.2 per 1000 after age 85, with 1,106,000 hospital discharges for heart – HF is the leading cause of hospitalization in patients older than 65 – Cost of $24 to $50 billion annually. • Patients with New York Heart Association (NYHA) Class IV symptoms currently have a reported 1-year mortality rate of 30% to 50%. • Rates for NYHA Class I-II patients and Class II-III patients are 5% and 10% to 15%. • Major goals in the management is the prevention of progression.
  2. Heart Failure • Although many patients successfully achieve temporary relief

    of HF symptoms with medical management, the underlying pathophysiology inevitably progresses, – pharmacologic interventions alone eventually will become inadequate – A variety of surgical procedures can be performed to improve cardiac function and potentially arrest (or even reverse) the progression.
  3. Heart Failure Pathophysiology • Increases in end-diastolic ventricular volume and

    pressure trigger the release of endogenous natriuretic peptides that promote diuresis. • Activation of the sympathetic nervous system causes peripheral vasoconstriction and increases the inotropic state of the myocardium. – Act to decrease excessive preload and restore wall tension to normal • Maintain cardiac output (CO) and arterial blood pressure (BP) in the face of mildly depressed ventricular function. – Eventually, the carotid, ventricular, and aortic arch baroreceptors are activated by the relative hypovolemia • leads to further activation of the sympathetic nervous system the renin-angiotensin-aldosterone axis, and the release of vasopressin. – The resultant peripheral vasoconstriction, mild fluid retention, and further increases in heart rate and inotropy will again compensate for the failing heart.
  4. Heart Failure Pathophysiology – Ultimately, however, chronic sympathetic stimulation causes

    myocardial β1-adrenergic receptors to downregulate, and as ventricular function deteriorates, left ventricular (LV) end-diastolic volumes and pressures again increase – Results in adverse myocardial remodeling. • Dilation and hypertrophy – Progresses to decreased Cardiac Output, increased oxygen demand and so begins the vicious cycle • Increased LA and pulmonary pressures → RV failure
  5. Heart Failure Medical Management • Agents that have been shown

    to decelerate the progression to severe failure, reduce adverse myocardial remodeling, and enhance survival – ACEI – Beta Blockers – Aldosterone Antagonists – Agents that improve symptoms but not long term survival • Diuretics • Digoxin
  6. Heart Failure Surgical Management of HF • Cardiac resynchronization therapy

    with biventricular pacing • Revascularization (coronary artery bypass grafting or percutaneous coronary artery stenting) • Mitral valve repair or replacement • Surgical ventricular restoration • Implantation of a left ventricular assist device • Cardiac transplantation • New therapies for congestive heart failure in various stages of development include transplantation of skeletal myoblasts and stem cells, “gene” therapy, and xenotransplantation
  7. Heart Failure Revascularization • Coronary artery disease has become the

    most common cause of HF • Where viable myocardium and feasible targets exist, revascularization of chronically ischemic, hibernating myocardium can improve ventricular function, downgrade NYHA functional class, and improve prognosis. – Ischemic • Insufficient oxygen supply to meet myocardial oxygen demand – Stunned • Acute myocardial dysfunction after an ischemic event with potential for full recovery – Hibernating • Chronically ischemic, dysfunctional myocardium with potential for full recovery – Maimed • Dysfunctional myocardium on the basis of ischemia that does not fully recover – Infarcted – Myocardial necrosis caused by ischemia with no potential for recovery
  8. Heart Failure Viability • If this tissue is not viable,

    then no reason to revascularize – Dobutamine stress echocardiography • improvement in mechanical contraction under pharmacologic stimulation – Single-photon emission computed tomography – Positron emission tomography – Cardiac magnetic resonance imaging • Nuclear Medicine Thallium Viability Scan – Injection of Thallium – Thallium taken into good portions of heart muscle and not absorbed by scarred/dead tissue – Pictures taken at various intervals show amount of thallium tracer
  9. Heart Failure Coronary Artery Bypass Grafting (CABG) • On Pump

    – Beating Heart – Arrested Heart • Aortic Cross Clamping • Cardioplegia • Cooling • Off Pump – OPCAB • Grafting – LIMA to LAD – SVG Harvest
  10. Heart Failure Mitral Regurgitation • Prone to valve dilation with

    heart failure and dilated LV as well as restriction of leaflets during systole
  11. Heart Failure Mitral Valve Repair • Annuloplasty Ring – Reduce

    amount of MR – Decrease EDV and Reversal of Flow
  12. Heart Failure ECMO • Extracorporeal membrane oxygenation – providing both

    cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of gas exchange to sustain life. • Hypoxemic respiratory failure • Cardiogenic Shock • Cardiac Arrest • Failure to wean from CPB • Bridge to Transplant or VAD
  13. Heart Failure ECMO • VV or VA – Veno-Venous •

    cannulae placed in the right common femoral vein for drainage and right IJ for infusion. • Alternatively, a dual-lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cavae and returning it to the right atrium. – Veno-arterial (VA) • Venous Cannula placed in Right CFV for drainage and Arterial Cannula placed into RFA. • Central ECMO – If Chest is open – Cannulate RA and Ascending Aorta
  14. Heart Failure Intra-Aortic Balloon Pump - Increase Coronary Perfusion -

    Decrease O2 Demand/Increase O2 Supply - Increase Cardiac Output - Decrease afterload - Counterpulsation - Deflates in systole - Inflates during diastole - Helium - Low Viscosity allows quick travel of gases
  15. Heart Failure Indications/Contraindications - Cardiogenic Shock - Unstable Angina Pectoris

    - Weaning from CPB - Left Main Disease - High Risk PCI Contraindications - Severe AI - Aortic Dissection - Severe Vascular Disease - Sepsis - Aortic/Aortafemoral Grafts - AAA
  16. Heart Failure Centrimag • Abbott Labs • Can be used

    as LVAD or RVAD or ECMO • Requires Anticoagulation – Usually heparin infusion • LV – Inflow to device from LV Apex – Outflow to Ascending Aorta • RV – Inflow to device from RA – Outflow to Pulmonary Artery
  17. Heart Failure Impella • Abiomed • Both LV and RV

    Support • Anticoagulation contained in “Purge Solution” • Heparin for antithrombosis • Dextrose for lubrication of device
  18. Heart Failure HEARTMATE III • Abbott • Durable LVAD •

    For Bridge to Transplant or Destination Therapy • Required to be anticoagulated
  19. Heart Failure • Many patients are “medical optimized” on medications

    – Beta Blockers – ACEI (Withhold or not) – Diuretics – Intravascular volume • Anxiolytic medications – Patients will not tolerate sudden decreases in sympathetic tone, hypoxemia, or PVR from hypercarbia
  20. Heart Failure • Most cases to improve cardiac function require

    CBP, but not always – Avoid depression of cardiac function and increases in afterload • Increase oxygen demand
  21. Heart Failure • Sedation – Failing heart is compensated by

    high catecholamine state • Removal of sympathetic tone may lead to CV collapse – Hypercarbia, hypoxemia, hypotension, Tachy/Brady/loss of Sinus • Renal or Hepatic Insufficiency – Affect anesthetic drug choices • Intravascular volume – What is optimization? • DRUGS – Ephedrine – Phenylephrine – Epi/Levo – Vasopressin – Milrinone
  22. Heart Failure • High Opioid technique – Induction with high

    doses fentanyl or sufentanil with NMB • Amnesia? • Chest wall rigidity? • Significant Bradycardia • Etomidate – No change in contractility • Propofol – Induction with decreases in SVR
  23. Heart Failure • Inhalation agents – High doses poorly tolerated

    • Myocardial depressants – Iso/Des causes more decreases in SVR than SEVO • Ketamine – 1 – 2.5 mg/kg IV • Hemodynaic stability with analgesia and amnesia • Sympathetic Side effects • PERICARDIAL TAMPONADE DRUG OF CHOICE
  24. Heart Failure • Central Venous Access – PA/Swan placement (PA/CVP/CO/CI)

    – Use of pharmacologic agents • TEE – Monitoring device – Direct Visualize the Heart •
  25. Heart Failure CASE 1 • A 55-year-old man with dilated

    cardiomyopathy (DCM) presented for open reduction and internal fixation of a tibial fracture. He had been in a motor vehicle accident. • Past medical history included alcohol abuse, orthopnea, dyspnea on exertion, and several episodes of pulmonary edema. The patient’s medications included digoxin, furosemide, and captopril. Physical examination revealed bibasilar rales and S3 gallop. A gated blood pool scan showed a left ventricular ejection fraction of 15%. Cardiac catheterization indicated a cardiac index of 1.8 L/min/m2, 2+ mitral regurgitation, and no coronary artery disease.
  26. Heart Failure Monitors • EKG – Risk of Ventricular Arrhythmias/Heart

    Block – Ischemic Changes • Arterial BP – Continuous BP – ABG • Central Line – PA? • TEE?
  27. Heart Failure • A 60-year-old man with end-stage heart failure

    presented for colonoscopy. He had a left ventricular assist device (LVAD) as a bridge-to-transplantation. He last took warfarin 5 days ago.
  28. Heart Failure • Perioperative fluid management • Perioperative anticoagulation •

    Perioperative antibiotic prophylaxis • Perioperative management of pacemakers and implantable • cardioverter-defibrillators (ICDs) • Appropriate location for postoperative recovery (i.e., • Postoperative pain management
  29. Heart Failure • What anesthetic agents and techniques are appropriate

    for a patient with a left ventricular assist device?
  30. Heart Failure • No specific agents contraindicated – Take into

    account dysfunctional RV • GA usual choice – Patients anticoagulated • Superficial regional blocks or Bier Block • Intubation/Extubation criteria unchanged – Old LVAD considered Full Stomach • Extubate early – Avoid post op VAP – NO REASON TO KEEP INTUBATED
  31. Heart Failure • LVAD output determined by volume status –

    MAINTAIN, MAINTAIN, MAINTAIN • Hypovolemia leads to hypotension – Suckdown or Suction Effect • Euvolemia/slightly hypervolemic – If RV can handle • Prevent increased PVR – Avoid Hypercarbia, Hypoxia, Acidosis, Alpha Agonists • Surgical positioning • Increased intrathoracic pressure – Avoid high peep, large TV, increased insuflation